CN Patent

CN105440051B — 一种抗结核的噻吩吡啶衍生物

Assigned to Chongqing Pharmaceutical Research Institute Co Ltd · Expires 2019-07-05 · 7y expired

What this patent protects

本发明涉及一种抗结核的噻吩吡啶衍生物，为式I化合物或药学上可接受的盐，R1‑R5如本文定义，该化合物具有抗结核杆菌活性。还包括含有式I化合物的药物组合物以及治疗结核病的用途。

USPTO Abstract

本发明涉及一种抗结核的噻吩吡啶衍生物，为式I化合物或药学上可接受的盐，R1‑R5如本文定义，该化合物具有抗结核杆菌活性。还包括含有式I化合物的药物组合物以及治疗结核病的用途。

Drugs covered by this patent

bedaquiline-fumarate (BEDAQUILINE FUMARATE)

Patent Metadata

Patent number: CN105440051B
Jurisdiction: CN
Classification: —
Expires: 2019-07-05
Drug substance claim: No
Drug product claim: No
Assignee: Chongqing Pharmaceutical Research Institute Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.